X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing Morphogenesis’ lead personalized cancer vaccine, IFx-Hu2.0, designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria.
Lead Product(s): IFx-Hu2.0,Pembrolizumab
Therapeutic Area: Oncology Product Name: IFx-Hu2.0
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: TuHURA Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 23, 2023
Details:
The proceeds will be used to fund the advancement of the combined company’s immunotherapy-focused development pipeline, including IFx-Hu2.0, designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria.
Lead Product(s): IFx-Hu2.0,Pembrolizumab
Therapeutic Area: Oncology Product Name: IFx-Hu2.0
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 23, 2023
Details:
The Phase 1b study is a randomized, double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in obese subjects with non-alcoholic fatty liver disease (NAFLD).
Lead Product(s): CB4211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CB4211
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
The Phase 1b study is a randomized, double-blind, placebo-controlled evaluation of one dose level of CB4211 given once a day for four weeks in obese subjects with non-alcoholic fatty liver disease (NAFLD).
Lead Product(s): CB4211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CB4211
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
Under the agreement, NIAID will be provided with CohBar's CB5064 Analogs to test in preclinical models of COVID-19, such as the golden Syrian hamster SARS-CoV-2 model.
Lead Product(s): CB5064 Analogs
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Details:
Preclinical data shows that combination of a CB5138 Analog with nintedanib, the leading standard of care for treatment of Idiopathic Pulmonary Fibrosis (IPF), produced enhanced effects compared to nintedanib alone in mice.
Lead Product(s): CB5138 Analog peptides,Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
CohBar intends to use the net proceeds from the offering, together with its existing cash resources, for general corporate purposes, funding preclinical and clinical development of its peptides, increasing working capital, operating expenses and capital expenditures.
Lead Product(s): CB4211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CB4211
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Roth Capital Partners
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2020
Details:
CohBar has resumed the Phase 1b stage of its Phase 1a/1b clinical trial of CB4211, its lead candidate for the treatment of nonalcoholic steatohepatitis (NASH) and obesity.
Lead Product(s): CB4211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CB4211
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
CohBar’s poster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis (IPF).
Lead Product(s): MBT2
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020
Details:
The presentation highlights potential of MBT2 to Inhibit Fibrogenesis in Cultured Human Lung Cells and its efficacy in Mouse Models of Idiopathic Pulmonary Fibrosis (IPF).
Lead Product(s): MBT2
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
